MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Restricted cash$1,321K Marketable securities,current$146,239K Prepayments and otherreceivables$38,138K Cash and cashequivalents$490,002K Intangible assets$407K Operating right of useasset$185K Property, plant andequipment, net$383K Marketable securities, netof current portion$92,609K Total current assets$675,700K Total assets$769,284K Total liabilities andshareholders' equity$769,284K Total shareholders'equity$683,431K Total liabilities$85,853K Accumulated loss-$762,390K Accumulated othercomprehensive income$4,793K Additional paid-in capital$1,426,750K Lease liability, netof current portion$66K Total currentliabilities$85,787K Ordinary shares$14,278K Derivative warrantliabilities$57,272K Lease liability,current$136K Deferred revenue,current$3,987K Accrued expenses andother current...$15,422K Accounts payable$8,970K
Balance Sheet
source: myfinsight.com

NewAmsterdam Pharma Co N.V. (NAMSW)

NewAmsterdam Pharma Co N.V. (NAMSW)